LDX Share Price Performance
AU$0
-0.03 (-100.00%)
Price AU$0
Fair ValueAU$0.28
Share Pricen/a
Lumos Diagnostics Holdings Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
LDX Community Narratives
AN
Fair Value AU$0.28 5.4% overvalued intrinsic discount
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
Catalysts About Lumos Diagnostics Holdings Lumos Diagnostics Holdings focuses on point of care diagnostic tests that aim to support real time treatment decisions for physicians and patients. What are the underlying business or industry changes driving this perspective?Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$0.28
5.4% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
39.85% p.a.
Profit Margin
11.21%
Future PE
48.92x
Price in 2029
AU$0.35
Trending Discussion
Recently Updated Narratives
AN
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
Fair Value: AU$0.28 5.4% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lumos Diagnostics Holdings Limited Key Details
About LDX
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
